Evoke Pharma, Inc. (EVOK)
USD 2.24
(-0.24%)
USD 2.24
(-0.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 260.57 Thousand USD | 105.53% |
| 2022 | -4.71 Million USD | -14.09% |
| 2021 | -4.13 Million USD | -46.38% |
| 2020 | -2.82 Million USD | 48.91% |
| 2019 | -5.52 Million USD | -3.88% |
| 2018 | -5.31 Million USD | 30.74% |
| 2017 | -7.67 Million USD | 14.74% |
| 2016 | -9 Million USD | -108.88% |
| 2015 | -4.31 Million USD | 55.84% |
| 2014 | -9.76 Million USD | 54.04% |
| 2013 | -21.24 Million USD | -2559.27% |
| 2012 | 863.77 Thousand USD | 199.76% |
| 2011 | -865.87 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.7 Million USD | -1904.77% |
| 2024 Q2 | -4.17 Million USD | 11.16% |
| 2023 Q2 | -1.95 Million USD | 37.41% |
| 2023 FY | 260.57 Thousand USD | 105.53% |
| 2023 Q4 | 260.57 Thousand USD | 127.39% |
| 2023 Q3 | -951.45 Thousand USD | 51.3% |
| 2023 Q1 | -3.12 Million USD | 33.79% |
| 2022 Q2 | -8.45 Million USD | -212.86% |
| 2022 FY | -4.71 Million USD | -14.09% |
| 2022 Q4 | -4.71 Million USD | 34.49% |
| 2022 Q1 | -2.7 Million USD | 34.63% |
| 2022 Q3 | -7.19 Million USD | 14.85% |
| 2021 Q4 | -4.13 Million USD | 32.18% |
| 2021 Q3 | -6.09 Million USD | 47.64% |
| 2021 Q2 | -11.63 Million USD | 10.94% |
| 2021 FY | -4.13 Million USD | -46.38% |
| 2021 Q1 | -13.06 Million USD | -362.83% |
| 2020 Q3 | -4.14 Million USD | 28.8% |
| 2020 Q1 | -4.02 Million USD | 27.1% |
| 2020 Q2 | -5.81 Million USD | -44.37% |
| 2020 Q4 | -2.82 Million USD | 31.82% |
| 2020 FY | -2.82 Million USD | 48.91% |
| 2019 Q3 | -6.46 Million USD | 12.22% |
| 2019 Q2 | -7.37 Million USD | -87.76% |
| 2019 Q1 | -3.92 Million USD | 26.2% |
| 2019 FY | -5.52 Million USD | -3.88% |
| 2019 Q4 | -5.52 Million USD | 14.59% |
| 2018 FY | -5.31 Million USD | 30.74% |
| 2018 Q1 | -5.4 Million USD | 29.6% |
| 2018 Q4 | -5.31 Million USD | 19.02% |
| 2018 Q3 | -6.56 Million USD | -0.56% |
| 2018 Q2 | -6.53 Million USD | -20.81% |
| 2017 Q3 | -10.41 Million USD | 17.07% |
| 2017 Q2 | -12.55 Million USD | 14.32% |
| 2017 FY | -7.67 Million USD | 14.74% |
| 2017 Q4 | -7.67 Million USD | 26.25% |
| 2017 Q1 | -14.65 Million USD | -216.66% |
| 2016 Q4 | -4.62 Million USD | 55.41% |
| 2016 FY | -9 Million USD | -108.88% |
| 2016 Q2 | 270.78 Thousand USD | 115.83% |
| 2016 Q3 | -10.37 Million USD | -3933.27% |
| 2016 Q1 | -1.71 Million USD | 60.34% |
| 2015 Q1 | -7.29 Million USD | 25.33% |
| 2015 FY | -4.31 Million USD | 55.84% |
| 2015 Q4 | -4.31 Million USD | 32.31% |
| 2015 Q3 | -6.37 Million USD | -15.2% |
| 2015 Q2 | -5.52 Million USD | 24.16% |
| 2014 Q1 | -19.23 Million USD | 9.45% |
| 2014 Q2 | -16.04 Million USD | 16.59% |
| 2014 FY | -9.76 Million USD | 54.04% |
| 2014 Q4 | -9.76 Million USD | 19.81% |
| 2014 Q3 | -12.17 Million USD | 24.11% |
| 2013 Q4 | -21.24 Million USD | -2.18% |
| 2013 Q1 | 1.26 Million USD | 46.69% |
| 2013 Q2 | 1.89 Million USD | 49.32% |
| 2013 Q3 | -20.78 Million USD | -1198.84% |
| 2013 FY | -21.24 Million USD | -2559.27% |
| 2012 FY | 863.77 Thousand USD | 199.76% |
| 2012 Q4 | 863.77 Thousand USD | 0.0% |
| 2011 FY | -865.87 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 85.852% |
| Alpha Teknova, Inc. | 1.97 Million USD | 86.8% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 99.723% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 99.652% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 99.94% |
| Cosmos Health Inc. | 8.59 Million USD | 96.967% |
| Journey Medical Corporation | -9.7 Million USD | 102.684% |
| Embecta Corp. | 1.31 Billion USD | 99.98% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 99.943% |
| Dynavax Technologies Corporation | 106.63 Million USD | 99.756% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 100.199% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 99.94% |
| PainReform Ltd. | -7.95 Million USD | 103.278% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 101.667% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 101.667% |
| SCYNEXIS, Inc. | -19.35 Million USD | 101.347% |
| Safety Shot Inc | -2.28 Million USD | 111.407% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 102.763% |
| Procaps Group, S.A. | 242.93 Million USD | 99.893% |
| Theratechnologies Inc. | 24.87 Million USD | 98.952% |
| Harrow Health, Inc. | 116.41 Million USD | 99.776% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 110.34% |
| Biofrontera Inc. | 4.05 Million USD | 93.576% |
| DURECT Corporation | -7.65 Million USD | 103.404% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 100.777% |
| Cronos Group Inc. | -663.32 Million USD | 100.039% |
| OptiNose, Inc. | 58.06 Million USD | 99.551% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 99.958% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 101.788% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 105.025% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 98.264% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 104.097% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -143.848% |
| Radius Health, Inc. | 359.28 Million USD | 99.927% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -32.131% |
| ProPhase Labs, Inc. | 19.23 Million USD | 98.645% |
| Phibro Animal Health Corporation | 454.84 Million USD | 99.943% |
| Procaps Group S.A. | 242.93 Million USD | 99.893% |
| Alvotech | 1.06 Billion USD | 99.976% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 92.915% |
| Viatris Inc. | 17.13 Billion USD | 99.998% |
| Rockwell Medical, Inc. | 4.45 Million USD | 94.152% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 105.343% |
| SIGA Technologies, Inc. | -148.68 Million USD | 100.175% |
| Tilray Brands, Inc. | 158.97 Million USD | 99.836% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 99.786% |
| Shineco, Inc. | 29.29 Million USD | 99.11% |
| PetIQ, Inc. | 351.93 Million USD | 99.926% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 108.981% |
| Incannex Healthcare Limited | -5.48 Million USD | 104.751% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 99.853% |
| Alimera Sciences, Inc. | 55.3 Million USD | 99.529% |
| Silver Spike Investment Corp. | -32.61 Million USD | 100.799% |
| Assertio Holdings, Inc. | -32.52 Million USD | 100.801% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 117.503% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 105.149% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 105.413% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 103.173% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 93.821% |
| Hempacco Co., Inc. | 13.61 Million USD | 98.086% |
| Talphera, Inc. | -5.72 Million USD | 104.555% |
| Alvotech | 1.06 Billion USD | 99.976% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 96.353% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 100.269% |
| Currenc Group, Inc. | -16.57 Million USD | 101.572% |
| Kamada Ltd. | -46.43 Million USD | 100.561% |
| Indivior PLC | -33.95 Million USD | 100.767% |
| Flora Growth Corp. | -713 Thousand USD | 136.546% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 103.173% |
| Evolus, Inc. | 63.7 Million USD | 99.591% |
| HUTCHMED (China) Limited | -197.45 Million USD | 100.132% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 99.946% |
| Akanda Corp. | 3.9 Million USD | 93.327% |